Efficacy of topical Risedronate and Risedronate - Eudragit E complex in a model of cutaneous leishmaniasis induced by Leishmania (Leishmania) amazonensis

GUZMAN MARIA LAURA; PERALTA, MA. FLORENCIA; MARIA E OLIVERA ME; CARRER, DOLORES; BARROSO PAOLA

Córdoba

Congreso; 6ta Reunión Internacional de Ciencias Farmacéuticas (RICiFa 2020+1) EVENTO VIRTUAL; 2021

An efficacious topical treatment for cutaneous leishmaniasis (CL) is desirable but still an ongoing challenge. Systemic risedronate (Ris) has been reported to have antileishmanial properties and Eudragit EPO (EuE) has shown in vitro activity against L.(L.) amazonensis. The aim of this work was to investigate the in vivo efficacy of topical Ris and EuE-Ris complexes on CL. In vivo antileishmanial activity was assessed in a BALB/c mice infected intradermally with promastigotes of L.(L.) amazonensis. The lesions were topically treated twice-daily with EuE-Ris and Ris in HPMC-hydrogels. Lesion appearance, immunoglobulin levels, smears and parasitic inhibition in the lesions, were analyzed in comparison with an untreated group.Ris and EuE-Ris treatments significantly reduced lesions size and flattened edges and ulcers compared to untreated mice. Besides, a marked parasitic inhibition of the lesions was found (69.5% and 73.7% respectively). At the end of the treatment, remaining parasites were found in both groups, however, the amastigotes in EuE-Ris group showed vacuoles and a less compact nucleus suggesting a higher efficacy, probably related to the antileishmanial complementary action of EuE. The IgG2a/IgG1 difference ratios tended to increase in both groups. The results are promising and the system should now be enhanced to achieve total parasite elimination.